COSCIENS Biopharma's receivables is $2.4M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
COSCIENS Biopharma (CSCIF) currently reports a receivables of $2.4M as of June 2026. That compares with $2.8M in the prior-year period — down 15.0% year over year. Use the charts on this page to explore COSCIENS Biopharma's receivables history and peer comparisons.
COSCIENS Biopharma's receivables decreased from $2.8M to $2.4M — a 15.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
COSCIENS Biopharma reported $2.4M in receivables as of June 2026. That compares with $2.8M in the prior-year period — down 15.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $2.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following CSCIF for alerts when major investors trade the stock.
COSCIENS Biopharma is classified in the Healthcare sector. On receivables, it currently shows $2.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSCIF with unrelated industries.